0.749
-0.01 (-1.58%)
| Penutupan Terdahulu | 0.761 |
| Buka | 0.780 |
| Jumlah Dagangan | 5,577,133 |
| Purata Dagangan (3B) | 2,363,076 |
| Modal Pasaran | 89,790,808 |
| Harga / Pendapatan (P/E Ke hadapan) | 4.54 |
| Harga / Jualan (P/S) | 2.97 |
| Harga / Buku (P/B) | 1.13 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Aug 2025 - 11 Aug 2025 |
| Margin Operasi (TTM) | -139.14% |
| EPS Cair (TTM) | -1.43 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.93% |
| Nisbah Semasa (MRQ) | 1.62 |
| Aliran Tunai Operasi (OCF TTM) | -170.49 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -83.05 M |
| Pulangan Atas Aset (ROA TTM) | -61.64% |
| Pulangan Atas Ekuiti (ROE TTM) | -138.71% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Invivyd, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 1.38 |
|
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 41.18% |
| % Dimiliki oleh Institusi | 71.29% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Mithril Ii Gp Lp | 31 Dec 2024 | 11,241,580 |
| M28 Capital Management Lp | 31 Dec 2024 | 9,248,250 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 10.00 (HC Wainwright & Co., 1,236.01%) | Beli |
| Median | 9.50 (1,169.21%) | |
| Rendah | 9.00 (D. Boral Capital, 1,102.41%) | Beli |
| Purata | 9.50 (1,169.21%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 0.697 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| D. Boral Capital | 16 May 2025 | 9.00 (1,102.40%) | Beli | 0.777 |
| 20 Mar 2025 | 9.00 (1,102.40%) | Beli | 0.739 | |
| HC Wainwright & Co. | 26 Mar 2025 | 10.00 (1,236.01%) | Beli | 0.616 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |